News
Antibody Developability by Design; Introducing ADD™
Fusion Antibodies is pleased to introduce our unique Antibody Developability by Design platform or ADD™.
Our ADD™ platform helps advance novel biologics through clinical development and to the market.
Here at Fusion Antibodies, our team can assess and optimize the developability profile of your antibody at the earliest stages to deliver the best possible antibody sequence. With years of experience in antibody engineering and manufacturing cell line development, Fusion Antibodies understands what it takes to deliver the optimal antibody sequence.
Our platform provides cost-effective solutions to mitigate risk throughout your antibody development program, offering the best chances of success in the clinic.
Read more about our unique ADD™ platform here or email us at info@fusionantibodies.com today and speak with one of our team about how we can help with your individual project.
We begin with the end in mind.
